For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

U.S.-listed shares of Verona Pharma ( VRNA) soared to an all-time high Wednesday after Merck ( MRK) agreed to pay about $10 ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...